Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

BCTX
Briacell Therapeutics Corp. Common Shares
stock NASDAQ

At Close
Mar 6, 2026 3:59:50 PM EST
3.84USD-4.239%(-0.17)186,040
3.83Bid   4.97Ask   1.14Spread
Pre-market
Mar 6, 2026 8:29:30 AM EST
4.12USD+2.686%(+0.11)650
After-hours
Mar 6, 2026 4:06:30 PM EST
3.87USD+0.794%(+0.03)1,600
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 19, 2022
04:58PM EST  BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (BriaCell or the Company), is pleased to announce that all resolutions proposed to shareholders at the Annual and Special Meeting of Shareholders (the Meeting) held virtually via teleconference on January 18, 2022 were passed. Voting for each of the director nominees was as follows:   GlobeNewswire Inc
Jan 10, 2022
04:11AM EST  BCTX: Game, Set and Match: HLAs Score Success   Benzinga
Dec 29, 2021
08:48PM EST  BriaCell to Uplist and Trade on the Toronto Stock Exchange from   GlobeNewswire Inc
Dec 16, 2021
08:50AM EST  Benzinga Pro's Top 5 Stocks To Watch For Thursday, Dec. 16, 2021: RIVN, BCTX, SLNH, SNAX, FWBI   Benzinga
08:23AM EST  BriaCell Highlights Certain Members Of Co. Board, Mgmt. Team Have Indicated Intent To Use Personal Funds To Buy ~10% Of Common Stock, Or ~1.59M Shares   Benzinga
08:00AM EST  -- Insiders intend to acquire up to approximately 10% of BriaCells basic common shares, or 1.59 million shares -- Corporate buyback program will continue; 501,703 shares and 143,236 warrants repurchased since program commencement -- $5.1 million proceeds received via warrant exercises since November 1, 2021   GlobeNewswire Inc
Dec 9, 2021
09:55PM EST  From Benzinga's Global Small Cap Conference: BriaCell Therapeutics CEO Bill Williams Says Thinks In 2H 2022 Will Be Able To Negotiate Pivotal Study Design In End Of Phase 2 Meeting   Benzinga
09:55PM EST  From Benzinga's Global Small Cap Conference: BriaCell Therapeutics CEO Bill Williams On Buyback Says Goal Was To Decrease Float, Align Co. With Investors   Benzinga
09:55PM EST  From Benzinga's Global Small Cap Conference: BriaCell Therapeutics CEO Bill Williams Discusses Development Timeline And Anticipated Milestones   Benzinga
09:55PM EST  From Benzinga's Global Small Cap Conference: BriaCell Therapeutics CEO Begins Presentation   Benzinga
09:00AM EST  BriaCell Summarizes Clinical Data Poster Presented at the 2021 San   GlobeNewswire Inc
Nov 18, 2021
09:16AM EST  BriaCell Therapeutics Reports Added Mary Crowley Cancer Research Center As Clinical Trial Site For Its Phase 1, 2a Breast Cancer Study   Benzinga
09:00AM EST  BriaCell Adds Mary Crowley Cancer Research Center as a Clinical   GlobeNewswire Inc
Nov 12, 2021
09:00AM EST  BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (BriaCell or the Company), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, today announces the following updates:   GlobeNewswire Inc
Nov 5, 2021
09:00AM EDT  BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (BriaCell or the Company), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, announces the addition of Suzanne Ostrand-Rosenberg, Ph.D. to its Scientific Advisory Board.   GlobeNewswire Inc
Nov 2, 2021
09:00AM EDT  BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (BriaCell or the Company), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors.   GlobeNewswire Inc
Oct 5, 2021
09:00AM EDT  October is Breast Cancer Awareness Month   GlobeNewswire Inc
Sep 29, 2021
01:16PM EDT  From BZ's Small Cap Healthcare Conference: BriCell President, Director & CEO, William V. Williams Begins Speaking   Benzinga
08:13AM EDT  The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug   Benzinga
Sep 23, 2021
08:20AM EDT  BriaCell's Survival Story Could Mean a Better Chance of Survival for Women Suffering from Breast Cancer   Benzinga
08:00AM EDT  SmallCapVoice.com Inc. (SCV) announces the availability of a new interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT), to discuss three key achievements that support the Companys continued growth.   GlobeNewswire Inc
Sep 22, 2021
09:00AM EDT  BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (BriaCell or the Company), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announces that the TSX Venture Exchange (the TSXV) has accepted the Companys Notice of Intention to implement a normal course issuer bid (the Buyback).   GlobeNewswire Inc
08:59AM EDT  Briacell's Survival Story Could Mean a Better Chance of Survival for Women Suffering from Breast Cancer   Benzinga
Sep 16, 2021
09:00AM EDT  BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (BriaCell or the Company), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces today that the Company will be presenting at the Benzinga Healthcare Small Cap Conference, which is being held virtually on September 29-30, 2021.   GlobeNewswire Inc
Sep 9, 2021
09:06AM EDT  BriaCell Announces Securities Buyback To Purchase Up To 10% Of Common Shares   Benzinga
09:00AM EDT  BriaCell Announces Securities Buyback to Purchase up to 10% of   GlobeNewswire Inc
Sep 1, 2021
09:15AM EDT  BriaCell Therapeutics Appoints Marc Lustig to its Board of Directors   GlobeNewswire Inc
Aug 23, 2021
08:00AM EDT  BriaCell to Participate at the H.C. Wainwright 23rd Annual Global   GlobeNewswire Inc
Aug 19, 2021
10:09AM EDT  BriaCell Therapeutics shares were trading higher after the company, and ImaginAb, announced a collaboration to evaluate immunotherapy imaging technology in advanced breast cancer.   Benzinga
08:30AM EDT  BriaCell And ImaginAb Announce Collaboration To Evaluate Immunotherapy Imaging Technology In Advanced Breast Cancer   RTTNews
08:00AM EDT  BriaCell and ImaginAb Announce Collaboration to Evaluate   GlobeNewswire Inc
Aug 17, 2021
03:36PM EDT  BiaCell Therapeutics To Delist Shares From Frankfurt Stock Exchange, Will Remain Listed On Nasdaq   Benzinga
Aug 16, 2021
03:14PM EDT  BriaCell Therapeutics Attacks Cancer with Novel Off-the-Shelf Immunotherapies   Benzinga
Aug 9, 2021
06:10AM EDT  Ault Global Holdings Reports 6.15% Stake in Briacell Therapeutics in 13D Filing; Says Purchased Briacell Therapeutics Shares Based on Belief That Shares, When Purchased, Were Undervalued   Benzinga
Jul 14, 2021
08:30AM EDT  BriaCell's Early-Stage Combination Study In Advanced Breast Cancer Starts Enrollment   Benzinga
07:24AM EDT  BriaCell Phase I/IIa Clinical Trial Combination Study in Advanced   GlobeNewswire Inc
07:22AM EDT  BriaCell Announces Phase I/IIa Clinical Trial Combination Study In Advanced Breast Cancer Patients Open For Enrollment   Benzinga
Jul 12, 2021
08:00AM EDT  BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (BriaCell or the Company), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, today announced that Dr. William V. Williams, President & CEO of BriaCell, is scheduled to present in the following virtual conferences:   GlobeNewswire Inc
Jun 16, 2021
12:03PM EDT  Mid-Day Market Update: Dow Falls 40 Points; Aprea Therapeutics Shares Surge   Benzinga
09:29AM EDT  BriaCell Extends Personalized Breast Cancer Immunotherapy To Prostate & Lung Cancer And Melanoma   Benzinga
08:07AM EDT  BriaCell Therapeutics Announces It Is Expanding Breast Cancer Platform Into Prostate, Melanoma And Lung Cancers   Benzinga
08:05AM EDT  -- BriaCell is expanding its breast cancer platform technology into other cancers including prostate, melanoma, and non-small cell lung cancer. -- Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer, remains on track to enter the clinic in 2021.   GlobeNewswire Inc
Jun 14, 2021
01:19PM EDT  CVI Investments Reports In 13G Filing A 5% Stake In BriaCell Therapeutics   Benzinga
Jun 10, 2021
08:09AM EDT  BriaCell Therapeutics Announces Proceeds Of US$12.88M From Warrant Exercises   Benzinga
08:05AM EDT  BriaCell Therapeutics Announces Proceeds of US$12.88 Million from   GlobeNewswire Inc
Jun 9, 2021
08:05AM EDT  BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (BriaCell or the Company), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that CEO Dr. William V. Williams will host a corporate and clinical update call on Wednesday, June 16, 2021 at 4:30 p.m. ET.   GlobeNewswire Inc
Jun 7, 2021
07:50PM EDT  BriaCell Therapeutics Corp. Announces Closing of US$27.2 Million   GlobeNewswire Inc
Jun 3, 2021
09:42AM EDT  BriaCell Therapeutics Reports Private Placement Of ~5.17M Units At $5.26/unit   Benzinga
09:42AM EDT  BriaCell Therapeutics Announces $27.2M Private Placement   Benzinga
09:42AM EDT  BriaCell Therapeutics Corp. Announces US$27.2 Million Private   GlobeNewswire Inc
08:23AM EDT  The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout   Benzinga
Jun 2, 2021
02:39PM EDT  Mid-Afternoon Market Update: Constellation Pharmaceuticals Surges Following Acquisition News; Protalix BioTherapeutics Shares Slide   Benzinga
12:30PM EDT  Mid-Day Market Update: Crude Oil Rises 1%; iRhythm Technologies Shares Plunge   Benzinga
10:24AM EDT  Mid-Morning Market Update: Markets Open Higher; Advance Auto Parts Profit Tops Estimates   Benzinga
09:15AM EDT  BriaCell Stock Doubles After Reporting Overall Survival Benefit in Pretreated Breast Cancer Patients   Benzinga
07:20AM EDT  BriaCell Provides Update On 12-Month Overall Survival Data On Previously-Disclosed Breast Cancer Patients; Top Responder Showed 100% Resolution of 'Eye-Bulging' Orbital Tumor   Benzinga
07:12AM EDT  -- 12.0 months average overall survival benefit, including 13.4 months in patients with 2+ HLA matches and 12.5 months in patients with Grade I/II tumors(1) -- Top Responder: 21.4 months survival plus 100% resolution of eye-bulging orbital tumor -- Compares to 7.2-9.8 months survival in historical comparison treatment trials(2)   GlobeNewswire Inc
May 19, 2021
05:15PM EDT  BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting   GlobeNewswire Inc
May 13, 2021
05:13PM EDT  Small-Cap Biotech Execs On Latest Advancements, Post-Pandemic Return To Fundamentals   Benzinga
12:32PM EDT  From BZ Global Small-Cap Event: BriaCell Therapeutics CEO Dr. Bill Williams Says Co Is Currently Dosing Bria-IMT With Incyte's Selected Compounds Under A Corporate Collaboration   Benzinga
12:25PM EDT  From BZ Global Small-Cap Event: BriaCell Therapeutics CEO Dr. Bill Williams Says Co Is Advancing Towards Pivotal Early 2022 Registration Study Commencement   Benzinga
May 11, 2021
06:30AM EDT  BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (BriaCell or the Company), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced that Dr. William V. Williams, President & CEO of BriaCell, is scheduled to participate in the following virtual conferences:   GlobeNewswire Inc
Apr 21, 2021
08:00AM EDT  SmallCapVoice.com Inc. (SCV) announces the availability of a new interview with Bill Williams, M.D., President and CEO of BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX-V: BCT) (the Company), to discuss the Companys targeted immunotherapies for breast cancer and its unique position as a clinical-stage biotech company.   GlobeNewswire Inc
07:31AM EDT  The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue   Benzinga
Apr 15, 2021
06:00PM EDT  BriaCell Announces Investor and Media Outreach Programs   GlobeNewswire Inc
Apr 12, 2021
01:45PM EDT  BriaCell Announces Closing of Over-Allotment Option in Connection   GlobeNewswire Inc
08:42AM EDT  BriaCell Stock Is Trading Higher After Encouraging Bria-IMT Data At AACR Annual Meeting   Benzinga
06:41AM EDT  BriaCell Therapeutics Presents Clinical Trials Of Bria-IMT Alone And In Combination With Immune Checkpoint Inhibitors   RTTNews
06:32AM EDT  BriaCell Therapeutics Presents Clinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021   Benzinga
06:30AM EDT  Clinical and pathological data presented from the clinical trials of Bria-IMT alone and in combination with immune checkpoint inhibitors in advanced breast cancer indicates high responding subset with protracted progression-free survival:   GlobeNewswire Inc
Mar 30, 2021
06:30AM EDT  BriaCell Therapeutics to Present at the American Association for   GlobeNewswire Inc
Feb 26, 2021
02:25PM EST  BriaCell Announces Closing of US$25 Million Public Offering   GlobeNewswire Inc
Feb 24, 2021
10:14AM EST  Mid-Morning Market Update: Markets Open Lower; Lowe's Beats Q4 Estimates   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC